The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Iberdomide with cyclophosphamide and dexamethasone in RRMM: first results from the ICON study
Charlotte Korst, MD, PhD, Amsterdam UMC, Amsterdam, Netherlands, discusses the ICON study (NCT04392037), investigating iberdomide combined with low-dose cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma (RRMM). Iberdomide is a novel cereblon E3 ligase modulator (CELMoD) with improved direct anti-myeloma activity and immune-stimulatory effects. This treatment regimen resulted in an overall response rate (ORR) of 82% and a median progression-free survival (PFS) of 17.8 months in patients with 2-4 prior lines of therapy. This fully oral, well-tolerated, and active combination warrants further evaluation in RRMM. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
